NGL Fine-Chem Limited β Q2FY27 earnings call summary
Filed 18 November 2026 Β· Official transcript
- Q2 FY27 revenue 158.71 Cr +32% y-y, EBITDA 28.06 Cr +64% y-y, margin 17.68%
- H1 FY27 revenue 297.87 Cr +33% y-y, PAT 34.64 Cr +84% y-y
- Tarapur Phase II commissioned Sep 24, 2026; utilization expected 30%-40% in 2-3 quarters
- Regulated markets (EU, US) filings ongoing; EU approvals expected by end 2027
- Price erosion for Fluralaner expected to stabilize in next 6 months
- Debt expected stable; short-term debt may rise with working capital needs
- Margins in regulated markets targeted at 18%-22%, overall long-term margin 15%-18%
- Inventory increased due to stock build and Gulf unrest; working capital discipline prioritized
Open source transcript Β· View NGL Fine-Chem Limited research
Sign in free to track NGL Fine-Chem Limited and receive future summaries.